CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
|
3 Months Ended |
Jun. 30, 2015 |
Jun. 30, 2014 |
| Cash Flows From Operating Activities: |
|
|
| Net loss |
$ (402,826)
|
$ (269,250)
|
| Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
| Depreciation and Amortization |
4,077
|
1,404
|
| Changes in assets and liabilities: |
|
|
| Prepaid expenses and other receivables |
9,085
|
(44,015)
|
| Accounts payable and other liabilities |
35,064
|
106,781
|
| Prepayment to related party for clinical trials |
177,794
|
(561,132)
|
| Net cash used in operating activities |
(176,806)
|
(766,212)
|
| Cash Flows from Investing Activities: |
|
|
| Increase in restricted cash |
0
|
(9,455)
|
| Purchase of intangible assets |
(48,611)
|
(1,373)
|
| Purchase of property and equipment |
(4,767)
|
0
|
| Net Cash used in investing activities |
(53,378)
|
(10,828)
|
| Cash Flows From Financing Activities: |
|
|
| Net cash provided by financing activities |
0
|
0
|
| Net decrease in cash |
(230,184)
|
(777,040)
|
| Effect of exchange rate changes on cash |
1,266
|
15,593
|
| Cash at beginning of period |
354,749
|
1,873,141
|
| Cash at end of period |
$ 125,831
|
$ 1,111,694
|